Literature DB >> 33381110

Systems Immunology Analysis Reveals an Immunomodulatory Effect of Snail-p53 Binding on Neutrophil- and T Cell-Mediated Immunity in KRAS Mutant Non-Small Cell Lung Cancer.

Sarah Musa Hammoudeh1,2, Thenmozhi Venkatachalam2, Abdul Wahid Ansari2, Riyad Bendardaf1,3, Qutayba Hamid1,4, Mohamed Rahmani1,2, Rifat Hamoudi1,2,5.   

Abstract

Immunomodulation and chronic inflammation are important mechanisms utilized by cancer cells to evade the immune defense and promote tumor progression. Therefore, various efforts were focused on the development of approaches to reprogram the immune response to increase the immune detection of cancer cells and enhance patient response to various types of therapy. A number of regulatory proteins were investigated and proposed as potential targets for immunomodulatory therapeutic approaches including p53 and Snail. In this study, we investigated the immunomodulatory effect of disrupting Snail-p53 binding induced by the oncogenic KRAS to suppress p53 signaling. We analyzed the transcriptomic profile mediated by Snail-p53 binding inhibitor GN25 in non-small cell lung cancer cells (A549) using Next generation whole RNA-sequencing. Notably, we observed a significant enrichment in transcripts involved in immune response pathways especially those contributing to neutrophil (IL8) and T-cell mediated immunity (BCL6, and CD81). Moreover, transcripts associated with NF-κB signaling were also enriched which may play an important role in the immunomodulatory effect of Snail-p53 binding. Further analysis revealed that the immune expression signature of GN25 overlaps with the signature of other therapeutic compounds known to exhibit immunomodulatory effects validating the immunomodulatory potential of targeting Snail-p53 binding. The effects of GN25 on the immune response pathways suggest that targeting Snail-p53 binding might be a potentially effective therapeutic strategy.
Copyright © 2020 Hammoudeh, Venkatachalam, Ansari, Bendardaf, Hamid, Rahmani and Hamoudi.

Entities:  

Keywords:  T-cell mediated anticancer immunity; immunomodulation; neutrophil-mediated anticancer immunity; non-small cell lung cancer; snail-p53 binding; systems immunology; tumor sensitization

Year:  2020        PMID: 33381110      PMCID: PMC7768232          DOI: 10.3389/fimmu.2020.569671

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  50 in total

1.  SSAHA: a fast search method for large DNA databases.

Authors:  Z Ning; A J Cox; J C Mullikin
Journal:  Genome Res       Date:  2001-10       Impact factor: 9.043

2.  Antitumor effect of novel small chemical inhibitors of Snail-p53 binding in K-Ras-mutated cancer cells.

Authors:  S-H Lee; G-N Shen; Y S Jung; S-J Lee; J-Y Chung; H-S Kim; Y Xu; Y Choi; J-W Lee; N-C Ha; G Y Song; B-J Park
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

3.  PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.

Authors:  Vivek Verma; Rajeev K Shrimali; Shamim Ahmad; Winjie Dai; Hua Wang; Sumin Lu; Rahul Nandre; Pankaj Gaur; Jose Lopez; Moshe Sade-Feldman; Keren Yizhak; Stacey L Bjorgaard; Keith T Flaherty; Jennifer A Wargo; Genevieve M Boland; Ryan J Sullivan; Gad Getz; Scott A Hammond; Ming Tan; Jingjing Qi; Phillip Wong; Taha Merghoub; Jedd Wolchok; Nir Hacohen; John E Janik; Mikayel Mkrtichyan; Seema Gupta; Samir N Khleif
Journal:  Nat Immunol       Date:  2019-07-29       Impact factor: 25.606

4.  Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.

Authors:  Christiane Meyer; Alexandra Sevko; Marcel Ramacher; Alexandr V Bazhin; Christine S Falk; Wolfram Osen; Ivan Borrello; Masashi Kato; Dirk Schadendorf; Michal Baniyash; Viktor Umansky
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

5.  Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN.

Authors:  Zvi G Fridlender; Jing Sun; Samuel Kim; Veena Kapoor; Guanjun Cheng; Leona Ling; G Scott Worthen; Steven M Albelda
Journal:  Cancer Cell       Date:  2009-09-08       Impact factor: 31.743

6.  The 10,000 Immunomes Project: Building a Resource for Human Immunology.

Authors:  Kelly A Zalocusky; Matthew J Kan; Zicheng Hu; Patrick Dunn; Elizabeth Thomson; Jeffrey Wiser; Sanchita Bhattacharya; Atul J Butte
Journal:  Cell Rep       Date:  2018-10-09       Impact factor: 9.423

7.  HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes.

Authors:  Rina M Mbofung; Jodi A McKenzie; Shruti Malu; Min Zhang; Weiyi Peng; Chengwen Liu; Isere Kuiatse; Trang Tieu; Leila Williams; Seram Devi; Emily Ashkin; Chunyu Xu; Lu Huang; Minying Zhang; Amjad H Talukder; Satyendra C Tripathi; Hiep Khong; Nikunj Satani; Florian L Muller; Jason Roszik; Timothy Heffernan; James P Allison; Gregory Lizee; Sam M Hanash; David Proia; Rodabe Amaria; R Eric Davis; Patrick Hwu
Journal:  Nat Commun       Date:  2017-09-06       Impact factor: 14.919

8.  The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.

Authors:  Edmund Poon; Stefanie Mullins; Amanda Watkins; Geoffrey S Williams; Jens-Oliver Koopmann; Gianfranco Di Genova; Marie Cumberbatch; Margaret Veldman-Jones; Shaun E Grosskurth; Vasu Sah; Alwin Schuller; Corrine Reimer; Simon J Dovedi; Paul D Smith; Ross Stewart; Robert W Wilkinson
Journal:  J Immunother Cancer       Date:  2017-08-15       Impact factor: 13.751

9.  Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer.

Authors:  Hyejin Choi; Jiehui Deng; Shuai Li; Tarik Silk; Lauren Dong; Elliott J Brea; Sean Houghton; David Redmond; Hong Zhong; Jonathan Boiarsky; Esra A Akbay; Paul D Smith; Taha Merghoub; Kwok-Kin Wong; Jedd D Wolchok
Journal:  Cell Rep       Date:  2019-04-16       Impact factor: 9.423

10.  MEK1/2 Inhibitors Unlock the Constrained Interferon Response in Macrophages Through IRF1 Signaling.

Authors:  Lei Yang; Jeak Ling Ding
Journal:  Front Immunol       Date:  2019-08-27       Impact factor: 7.561

View more
  2 in total

Review 1.  Opposing Roles of Wild-type and Mutant p53 in the Process of Epithelial to Mesenchymal Transition.

Authors:  Oleg Semenov; Alexandra Daks; Olga Fedorova; Oleg Shuvalov; Nickolai A Barlev
Journal:  Front Mol Biosci       Date:  2022-06-23

2.  Identifying Immunological and Clinical Predictors of COVID-19 Severity and Sequelae by Mathematical Modeling.

Authors:  Noha M Elemam; Sarah Hammoudeh; Laila Salameh; Bassam Mahboub; Habiba Alsafar; Iman M Talaat; Peter Habib; Mehmood Siddiqui; Khalid Omar Hassan; Omar Yousef Al-Assaf; Jalal Taneera; Nabil Sulaiman; Rifat Hamoudi; Azzam A Maghazachi; Qutayba Hamid; Maha Saber-Ayad
Journal:  Front Immunol       Date:  2022-04-20       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.